Aurobindo Pharma subsidiary CuraTeQ Biologics and U.S. firm BioFactura have terminated their agreement relating to BFI-751, a proposed biosimilar to Janssen Biotech’s Stelara (Ustekinumab).

JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Belgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA ...

Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ ...

South Korean biotech Samsung Bioepis has secured Japanese marketing approval for its ustekinumab biosimilar, referencing Stelara (ustekinumab). The product will be commercialized by Japanese medical ...

Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Samsung Bioepis said Tuesday it has received approval from Japan’s Ministry of Health, Labor and Welfare for SB17, or ...

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...

"Takeda to seek approval of plaque psoriasis pill on Phase III trial data" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.